United States Imposes Up to 200 Percent Tariffs on Generic Drugs, Pressuring Indian Exporters

US Tariffs impose a phased schedule on generic medicines: zero percent for the first two years, rising to one hundred percent in the third year, and reaching two hundred percent thereafter, according to the announced policy.

Indian Pharma executives warn the steep duties are impossible to absorb, citing cost pressures that could erode profit margins and threaten supply chains for markets that rely on affordable Indian generics.

Export Growth shows Indian generic exporters have expanded shipments by 125 percent over the past nine years, with a top‑11 list of companies highlighted for 2026, underscoring the sector’s rising global role.

Industry Response includes plans to diversify markets, invest in innovative formulations, and seek alternative supply routes, as firms aim to mitigate tariff impact while maintaining competitiveness in the worldwide pharmaceutical arena.